GSTM1 and pulmonary fibrosis: In summary, this study supports further clinical evaluation of allosteric Hb modifiers as a novel therapeutic strategy for treating hypoxemia associated with pulmonary fibrosis and potentially retarding the progression of pulmonary fibrosis.